Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

This study has been terminated.
(MTD not determined)
Information provided by (Responsible Party):
Celgene ( Celgene Corporation ) Identifier:
First received: December 1, 2006
Last updated: April 6, 2012
Last verified: August 2008
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2008
  Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)